Should I admit a patient with a CK-MB level of 357 U/L?

Yes, admit this patient immediately.

A CK-MB of 357 U/L is markedly elevated and indicates significant myocardial injury requiring hospital admission for evaluation and management of acute coronary syndrome. This level far exceeds the 99th percentile upper reference limit used for diagnosing myocardial infarction 1, 2.

Why This Patient Requires Admission

Diagnostic Significance

• CK-MB should be measured by mass assay (not activity), with values above the 99th percentile URL indicating myocardial infarction 1
• Your patient's CK-MB of 357 U/L is substantially elevated regardless of which reference range is used
• While cardiac troponin is the preferred biomarker, CK-MB remains a valid alternative when troponin is unavailable and is still clinically useful for detecting reinfarction 1, 2

Prognostic Implications

The mortality and complication data are compelling:

• Elevated CK-MB predicts 25-49% increased relative risk of death or MI at 180 days in acute coronary syndrome patients 3
• A 2023 study found that CK-MB variation ≥354 U/L predicts mortality in STEMI patients 4 - your patient's value of 357 U/L crosses this threshold
• Patients with positive CK-MB have a 16-fold increased risk of ischemic complications (cardiac death, recurrent MI, arrhythmias, heart failure) compared to those with negative CK-MB 5
• Even minimally elevated CK-MB (1-24 IU/L) carries 22% one-year cardiac mortality when associated with chest pain, versus 6% in those with normal CK-MB 6

Clinical Algorithm for This Patient

Immediate actions upon admission:

1. Obtain serial cardiac biomarkers: Draw troponin immediately if available; repeat CK-MB at 6-9 hours to document rise/fall pattern 1
2. 12-lead ECG: Look for ST-segment elevation, new Q-waves, or dynamic ST-T changes 1
3. Continuous cardiac monitoring: Watch for ventricular arrhythmias, conduction defects 5
4. Risk stratification: Assess for heart failure, hemodynamic instability, or cardiogenic shock 5

Key diagnostic considerations:

• The rise and/or fall pattern of CK-MB distinguishes acute MI from chronic elevation (e.g., renal failure) 1
• If troponin is available and normal while CK-MB is elevated, consider alternative causes of CK-MB elevation: skeletal muscle injury, intestinal injury, or assay interference 2
• However, do not delay treatment waiting for biomarker confirmation if ECG shows diagnostic ST-elevation 2

Important Caveats

CK-MB specificity limitations:

• CK-MB constitutes 1-3% of skeletal muscle CK, so major trauma, surgery, or rhabdomyolysis can cause false positives 2
• Also present in intestine, diaphragm, uterus, and prostate 2
• If clinical picture doesn't fit cardiac ischemia, measure total CK to assess CK-MB/total CK ratio (should be >2.5-3% for MI)

Timing considerations:

• CK-MB typically returns to normal within 24-36 hours after MI 2
• If patient presents >24 hours after symptom onset, troponin (which stays elevated 7-14 days) is more reliable 1

The combination of markedly elevated CK-MB at this level, the strong mortality prediction data, and the 16-fold increased complication risk makes admission non-negotiable. This patient requires telemetry monitoring, serial biomarkers, cardiology consultation, and likely coronary angiography depending on ECG findings and clinical presentation.